vimarsana.com

Latest Breaking News On - Rastuzumab - Page 1 : vimarsana.com

ILD Not Increased With MTX in Patients With Dermatomyositis

Treatment with methotrexate was not associated with an increased risk for interstitial lung disease (ILD) in patients with dermatomyositis.

New yorkUnited statesJillt shahYork university langone healthNational institutesHealth sponsored allNew york university langone healthNew york cityBiologic therapyInterstitial lung diseaseAlignant neoplasiaAlignant neoplasmAntineoplastic drugNti cancer agentsMonoclonal antibodyElectronic health records

FDA Expands Enhertu Indication to HER2-Positive Solid Tumors

The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.

United statesUniversity of texas md anderson cancer centerDrug administrationDaiichi sankyo incDaiichi sankyoCancer centerBoxed warningBreast cancerAlignant breast neoplasmBreast carcinomaBiologic therapyAntineoplastic drugNti cancer agentsNoncolorectal gastrointestinal cancerOncolorectal gi cancerNt specialty

First-Line Highly Effective Therapy Better for Pediatric MS

New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis.

Department of pediatric neurologyUniversity angersExpanded disability status scaleNail benalleguePediatric neurologyMultiple sclerosis msS multiple sclerosisBiologic therapyAntineoplastic drugNti cancer agentsGlatiramer acetateInterferon betaFn betaInterferon betaMonoclonal antibody

Microfluidic Modulation Spectroscopy analysis of Trastuzumab and biosimilars: Structural integrity and stability assessment

This article presents a detailed investigation of Trastuzumab and its biosimilars, focusing on their structural integrity and stability.

Bruxelles capitaleUnited kingdomTrastuzumab herceptinMaria osipovaWaters corporationStructir labWood centreTechnology venture partnersJournal of pharmaceutical sciencesSponsored contentImage creditClinical oncologyPharmaceutical sciencesMicrofluidic modulation spectroscopyRedwood shoresIllumina ventures

How Does Rituximab for Pemphigus Fare in the Long Term?

This marks the first long-term follow-up data from patients in the Ritux 3 trial who received rituximab as a first-line agent.

Haute normandieBillal tedbirtDepartment of dermatologyBiologic therapyAntineoplastic drugNti cancer agentsMonoclonal antibody

vimarsana © 2020. All Rights Reserved.